Ascentage Pharma Group International

Healthcare · Biotechnology · China

Last price 14.4565 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.27B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...